Get started
Zai Lab LimitedZai Lab LimitedZai Lab Limited

Zai Lab Limited

No trades
OverviewFinancialsNewsCommunityTechnicalsForecastsSeasonalsOptionsETFs

What traders are saying


Join the conversation. Discover trade ideas, share insights, and see how others read the market.
Trade ideasMinds
Zai Lab (ZLAB) – Biotech Growth & Profitability PathCompany Overview: Zai Lab NASDAQ:ZLAB , a leading Chinese biotech firm, is on track for non-GAAP profitability by Q4 2025, driven by strong revenue growth & cost management. Key Catalysts: Financial Discipline & Expansion 💰 Operating losses fell 45% in Q4 2024, highlighting cost efficiency while scaling operations. Analysts project $2 billion in annual revenue by 2028, reinforcing long-term value creation. Blockbuster Drug Pipeline 💊 VYVGART generated $93.6M in its first full launch year, demonstrating strong adoption. KarXT & bemarituzumab are key upcoming growth drivers, expanding ZLAB’s market footprint. Investment Outlook: Bullish Case: We are bullish on ZLAB above $34.00-$35.00, supported by financial execution & product expansion. Upside Potential: Our price target is $54.00-$55.00, driven by strong product adoption & long-term growth trajectory. 🔥 Zai Lab – Unlocking the Future of Biotech Innovation. #ZLAB #Biotech #GrowthStocks
NASDAQ:ZLABLong
by Richtv_official
ZLAB $23.60 | Finding Value for 2025-2027 Payoutstumbled upon under rated pharma research preventive bio project in China and is staged to be a big player when it goes commercial and licensing deals with it new discoveries price is just decent at around $2.x bn cap yet as promising as illumina crispr moderna perhaps Eli Lily someday who knows when Vanguard takes into acount McKinseys study this can magically moon back to at least half way to all time highs Strategy: buy and forget
NASDAQ:ZLAB
by senyor
Long $ZLAB for a while$ZLAB is a Chinese biotech company specializing in the treatment of cancer, among other things. In December an insider bought 4,000 shares. Also, hedge funds have been increasing their exposure to $ZLAB for the last 4 quarters. The stop is 7% below at the red line. There are 2 upper trend lines (yellow). My feeling is that $ZLAB will be unsuccessful at getting through both of these levels of resistance. However, they are about 31% above. This is a more than 4:1 reward/risk ratio. Also note that $ZLAB has earnings on Mar 1 after hours. 87M float on this one
NASDAQ:ZLABLong
by itssean310